Royalty Pharma plc (RPRX) | Stock Overview & Key Data

Royalty Pharma plc | Large-cap | Healthcare

$35.09

0.72%

| Royalty Pharma plc Stock Comparison:

Royalty Pharma plc vs Vertex Royalty Pharma plc vs Regeneron Royalty Pharma plc vs Alnylam Royalty Pharma plc vs Insmed Royalty Pharma plc vs Incyte Royalty Pharma plc vs S&P 500 | Market

Chart Range Statistics Financials Returns Ownership Calculator FAQ

Royalty Pharma plc Performance Comparison

Loading chart data...

Royalty Pharma plc

Healthcare Sector

S&P 500

View Full Price History

Stock Range

Today's Range

Low: $34.58 High: $35.15

on June 16, 2025

52 Week Range

Low: $24.05 High: $35.38

on December 19, 2024

on June 13, 2025

All-Time High: $56.50 on June 15, 2020

Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights

Key Statistics

Market Cap i $19.6B

EPS i 2.45

P/E Ratio (TTM) i 14.22

Forward P/E i 7.94

P/B Ratio i 2.22

PEG Ratio i 7.94

Div. Yield i 2.47%

ROE i 18.00%

Beta i 0.474

Debt to Equity i 77.82

Financial Highlights

Profitability

Gross Margin i N/A

Operating Margin i 94.00%

Profit Margin i 48.26%

Returns and Earnings

Return on Assets (TTM) i 7.04%

Return on Equity (TTM) i 18.00%

EBITDA i $2.0B

Net Income (TTM) i $1.1B

Growth

Revenue (TTM) i

Revenue Per Share (TTM) i

Quarterly Revenue Growth i

Quarterly Earnings Growth i

Peer Performance Comparison

Company	Market Cap	1W	1M	3M	6M	YTD	1Y	3Y	5Y
Royalty Pharma plc RPRX	19.59B Large-cap	3.14%	6.15%	6.61%	40.26%	35.09%	29.42%	-11.46%	-28.90%
Vertex VRTX	116.96B Large-cap	1.10%	5.43%	-9.44%	-1.79%	12.25%	-5.26%	73.12%	55.30%
Regeneron REGN	57.14B Large-cap	7.30%	-7.82%	-22.24%	-27.63%	-26.00%	-48.94%	-8.90%	-17.81%
Alnylam ALNY	40.16B Large-cap	2.38%	15.41%	27.40%	25.48%	31.83%	92.03%	124.66%	104.36%
Insmed INSM	17.98B Large-cap	34.11%	50.25%	31.52%	37.83%	41.14%	54.46%	431.38%	241.39%
Incyte INCY	13.11B Large-cap	-1.48%	11.41%	0.06%	-1.17%	-2.56%	9.08%	-4.94%	-35.72%

Ownership & Short Interest

Insider Ownership i 8.92%

Institutional Ownership i 79.20%

Shares Short i 29M

Short Ratio i 4.79

Short % of Shares Outstanding i 7.00%

Average 10-Day Volume i 4M

Average 90-Day Volume i 6M

Royalty Pharma plc Recurring Investment / Dollar-Cost Averaging Calculator

Calculate how a regular investment in Royalty Pharma plc would have performed over time.

Investment Amount

Investment Frequency

Start Date

End Date (Optional)

If not specified, the latest available data will be used

Reinvest Dividends

Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.

Frequently Asked Questions

What is RPRX's 52-week high and low?

In the last 52 weeks, Royalty Pharma plc reached a high of $35.38 (on June 13, 2025) and a low of $24.05 (on December 19, 2024).

What is the market cap and P/E ratio for RPRX?

Curious about Royalty Pharma plc's size and valuation? Its market capitalization stands at 19.59B. When it comes to valuation, the P/E ratio (trailing twelve months) is 14.22, and the forward P/E (looking ahead) is 7.94.

Does RPRX pay dividends? If so, what's the yield?

Yes, Royalty Pharma plc is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 2.47%, and the company is expected to pay out $0.88 per share over the coming year.

Who are Royalty Pharma plc's main competitors or similar companies to consider before investing?

When looking at Royalty Pharma plc, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Vertex VRTX	116.96B	Healthcare	Biotechnology	-5.26%	73.12%
Regeneron REGN	57.14B	Healthcare	Biotechnology	-48.94%	-8.90%
Alnylam ALNY	40.16B	Healthcare	Biotechnology	92.03%	124.66%
Insmed INSM	17.98B	Healthcare	Biotechnology	54.46%	431.38%
Incyte INCY	13.11B	Healthcare	Biotechnology	9.08%	-4.94%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Royalty Pharma plc? (e.g., ROE, Debt/Equity)

To get a sense of Royalty Pharma plc's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 18.00%, the Debt to Equity ratio from the most recent quarter is 77.82, and its Gross Profit Margin stands at N/A.

What is the recent revenue and earnings growth for RPRX?

Looking at Royalty Pharma plc's growth, its revenue over the trailing twelve months (TTM) was $2B. Compared to the same quarter last year (YoY), quarterly revenue grew by -4.28%, and quarterly earnings saw a YoY growth of 4,888.50%.

How much of RPRX stock is held by insiders and institutions?

Wondering who owns Royalty Pharma plc stock? Company insiders (like executives and directors) hold about 8.92% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 79.20%.

For more common questions about our data, please visit our About Data page.

Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.